

TCM CD4 T cell infection extent before ART associated with immune failure and HIV persistence on ART

Vincent C. Marconi MD^{1,2,3}, Emily Ryan², Luca Micci PhD², Amelie Pagliuzza M.Sc⁴, Sol Aldrete MD¹, Keith Delman MD¹, Jacob Estes PhD⁵, Nicolas Chomont PhD⁶, Rafick Sekaly PhD⁷, Mirko Paiardini PhD²

¹Emory University School of Medicine, ²Yerkes Non-Human Primates Research Center, ³Rollins School of Public Health, ⁴Centre de recherche du CHUM, ⁵Frederick National Laboratory, Leidos Biomedical Research, ⁶Université de Montréal, ⁷Case Western Reserve University

Center for AIDS Research

Introduction

- Morbidity and mortality especially from severe non-AIDS conditions are increased for individuals with persistently low CD4 T cell counts (immune non-responders, INR) and/or persistent immune activation despite virologic suppression on antiretroviral therapy (ART)
- Current treatments to increase CD4 T cell counts or reduce immune activation have been unable to reduce morbidity or mortality
- Objective:** To determine if differential infection of CD4 T cell subsets prior to initiating ART could further explain divergent CD4 response to ART and maintenance of the latent HIV reservoir

Methods

- 30 HIV-positive participants were categorized into two groups based upon their CD4 response to ART-mediated virologic suppression and provided peripheral blood mononuclear cells (PBMCs) at time points before and after ART initiation. Median age of the cohort was 46; 90% were male, 82.8% were African-American
- Immunologic responders (IR) were defined as having CD4 counts >500 cells/ μ L < 2 years after ART initiation
- INR were defined as having CD4 counts <350 cells/ μ L > 2 years after ART initiation
- The frequency of PBMCs harboring total and integrated HIV DNA were measured in sorted naïve (N), central memory (CM), transitional memory (TM), and effector memory (EM) CD4 T cells for INR and compared to IR
- Immunological parameters - including frequencies of CD4 and CD8 T cells and of their N (CD45RA+CCR7+CD27+), CM (CD45RA-CCR7+CD27+), TM (CD45RA-CCR7-CD27+), and EM (CD45RA-CCR7-CD27-) subsets, their levels of proliferation, and the expression of immune checkpoint molecules (ICM) - were analyzed by flow cytometry

Results




Figure 1. Total (A,C) and integrated (B,D) HIV DNA pre-ART (A,B) and on ART (C,D) for immunologic responders (IR) and immunologic non-responders (INR) within naïve, CM, TM and EM CD4 T cell subsets.




Figure 2. Total (A) and integrated (B) HIV DNA trajectories for IR pre-ART (open circles) and post-ART (shaded circles) compared to INR pre-ART (open squares) and post-ART (shaded squares) within naïve, CM, TM and EM CD4 T cell subsets.

- Total and Integrated HIV-DNA content in all CD4 T-cell subsets were significantly higher ($P < 0.01$) prior to ART and on-ART in INR than IR (**Fig. 1**)
- HIV-DNA levels in IR were significantly reduced ($P < 0.01$) on-ART compared to pre-ART in all CD4 T-cell subsets whereas levels were more stable in INR CM & TM cells between post-ART and pre-ART time points (**Fig. 2**). Thus, long-lived CM and TM cells with HIV-DNA persist longer in INR compared to IR on ART.

Results




Figure 3. PD-1 (A,D), TIGIT (B,E), and Ki67 proliferation level (C,F) of blood CD4 (A-C) and CD8 (D-F) T cell subsets before ART initiation in IR and INR.

- Expression of ICM such as: PD-1 and TIGIT were significantly increased in memory CD4 T-cells (but not CD8) of INR ($P < 0.05$) before ART (but not during ART, not shown), despite similar levels of proliferation

Conclusions

- Compared to IR, INR demonstrate higher levels of ICM expression (pre-ART) and viral burden (both prior to and on-ART) in all memory CD4 T cell subsets.
- CM and TM CD4 T-cells harboring HIV-DNA persist longer during ART in INR.**
- These data link levels of CD4 T-cell infection prior to ART, particularly in long-lived CD4 T-cell subsets, with immune recovery and HIV persistence

Special thanks to patients and staff at the IDP for their generous contributions to this work especially Theron Stuart, Cameron Tran, Elena Morales, Tanisha Sullivan and Ericka Patrick. Funding for this work: NIH/NIAID (R01AI110334) and Emory CFAR (P30AI050409).